15% of the 2013 FDA-approved new molecular entities are cold-chain products
Percentage is down from last year’s figure
FDA approved 27 new molecular entities (NMEs) in 2013, down from the 39 approved in 2012, which was a recent banner year. Of the 27, Pharmaceutical Commerce’s analysis shows that 4, or 15% of the total, are cold chain products, requiring storage and transportation at 2-8°C. Last year’s figure (which included some vaccines and blood products not included here) was 38%. HDMA’s Factbook, among other sources, indicates that around 10% of current industry stockkeeping units require refrigeration, so purely on that basis, 2013’s approvals show a continuing trend toward more cold-chain products coming from the industry.
Among cold chain products, all of the 2013 approvals had simply a 2-8° requirement on their labels—no frozen product or other temperature ranges. Of the 23 room-temperature products, there continues to be a non-standardization that some in the industry believe is an unnecessary complication for supply chain managers. Some list the storage temperature at 20°C; some at 25°, and one at “below 40°C”. Most give an excursion range of 15-30°C—but the variable there is the duration of the excursion.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
